BMRN - CIK 0001048477
The table below shows BIOMARIN PHARMACEUTICAL INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $827.99M | $572.84M | $159.26M | $175.90M | $304.54M | $85.36M |
| Capital expenditure | $103.04M | $85.42M | $96.69M | $120.96M | $95.58M | $114.31M |
| Investing cash flow | -$414.24M | $136.49M | -$111.24M | -$20.03M | -$366.31M | -$53.62M |
| Dividends paid | - | - | - | - | - | - |
BIOMARIN PHARMACEUTICAL INC reported operating cash flow of $827.99M for fiscal year 2025. That is up 44.5% from $572.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$227.84M (FY 2016) to $827.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | $0.00 | $0.00 | $50.00M |
| Financing cash flow | -$42.39M | -$526.45M | -$18.73M | -$18.65M | -$48.00K | $181.12M |